Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.
作者信息
van Puijenbroek E P, Du Buf-Vereijken P W, Spooren P F, van Doormaal J J
机构信息
Netherlands Pharmacovigilance Foundation LAREB, Tilburg, The Netherlands.
出版信息
J Intern Med. 1996 Dec;240(6):403-4. doi: 10.1046/j.1365-2796.1996.48879000.x.
Abstract
The occurrence of rhabdomyolysis is one of the rare side-effects of the cholesterol-lowering agent simvastatin. During the use of lovastatin, an agent related to simvastatin, the risk of this side-effect might be increased when cyclosporin or gemfibrozil are used concomitantly. It is possible that this also applies for simvastatin. We present two patients who developed rhabdomyolysis during the concomitant use of simvastatin and gemfibrozil.
摘要
Zotero 插件